Short-Term Sirolimus Treatment Increases Cerebral Blood Flow In Asymptomatic APOE4 Females Determined By 3T MRI
Research Summary
A conference poster abstract describing what the authors call the first human study of whether rapamycin (sirolimus) changes cerebral blood flow in carriers of APOE4, the strongest genetic risk factor for late-onset Alzheimer’s disease. The same group had earlier reported that rapamycin restored brain blood flow in APOE4 mice.
Who Or What Was Studied?
Two cognitively normal women aged 45-65 who carry APOE4 (MoCA score above 28). They took sirolimus 1 mg per day for four weeks. Brain blood flow was measured with 3T arterial spin-labelling MRI at baseline, at weeks 2 and 4 of treatment, and two weeks after stopping (washout). There was no control group.
What Did The Research Show?
- Average blood flow increased in all brain areas examined. At washout, cortical blood flow was on average 34.8 ± 2.1% higher than at baseline.
- Within the cortex, the average increases were 41.5% (frontal), 28.2% (parietal), 37.4% (temporal) and 33.1% (occipital); white matter blood flow rose 33.7%.
- Smaller regions linked to Alzheimer’s disease also increased: entorhinal cortex 25.1%, hippocampus 21.4% and amygdala 23.6%.
- No side effects were observed, and blood glucose and HbA1c did not change.
Limitations And Interpretation
- Only two participants, both women, with no placebo or untreated comparison group, so the changes cannot be attributed to the drug with confidence.
- A short conference abstract, not a full peer-reviewed paper; methods and data are reported only briefly.
- Blood flow is an imaging measure: the study did not test memory, Alzheimer’s biomarkers or disease risk.
- The authors state that larger studies including men and non-carriers are still needed.
Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.